When compared to traditional molecular prognostic markers, such as IDH1 mutation [11], the NLR can appropriately assess the prognosis in glioblastoma (GBM) patients in order to guide therapeutic decisions and patient management. This evidence concerns the gene IDH1 and glioblastoma.